Overview

A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

Status:
Completed

Trial end date:
2020-12-29

Target enrollment:

Participant gender:

Summary

This study will examine the safety and efficacy of pertuzumab in combination with high-dose trastuzumab in adult participants with HER2-positive MBC with CNS metastases and disease progression in the brain following radiotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Pertuzumab
Trastuzumab